Abstract
Background/Aims
Methods
Results
REFERENCES
Fig. 1.
Fig. 2.
Fig. 3.
Table 1.
| Variables | CMI-EMR group (34 lesions in 34 patients) | Size-matched ESD group (102 lesions in 100 patientsa)) | p-value |
|---|---|---|---|
| Age, yr, mean±SD | 61.6±8.0 | 62.2±10.1 | 0.730 |
| Sex, male, n (%) | 18 (52.9) | 61 (59.8) | 0.482 |
| Antiplatelet agentsb), n (%) | 1 (2.9) | 1 (1.0) | 0.439 |
| Coagulopathy, n (%) | 0 | 0 | NA |
| Thrombocytopeniac), n (%) | 1 (2.9) | 0 | 0.250 |
| Size, mm, mean±SD | 22.3±3.9 | 22.9±2.4 | 0.268 |
| Locationd), n (%) | 0.289 | ||
| Right colon | 19 (55.9) | 45 (44.1) | |
| Left colon | 8 (23.5) | 21 (20.6) | |
| Rectum | 7 (20.6) | 36 (35.3) | |
| Morphology, n (%) | 0.999 | ||
| Is | 4 (11.8) | 13 (12.7) | |
| II (IIa, IIb, or IIa + IIc) | 30 (88.2) | 89 (87.3) | |
| Histology, n (%) | 0.258 | ||
| TA, TVA, or VA | 28 (82.4) | 81 (79.4) | |
| SSA/P | 5 (14.7) | 6 (5.9) | |
| Superficial submucosal cancer | 1 (2.9) | 8 (7.8) | |
| Deep submucosal cancer | 0 | 6 (5.9) | |
| Non-neoplastic lesions | 0 | 1 (1.0) |
Table 2.
Table 3.
| Variables | Korean CMI-EMR group (n=34) | US CMI-EMR group (n=30) | p-value |
|---|---|---|---|
| Age, yr, mean±SD | 61.6±8.0 | 67.6±7.9 | 0.004 |
| Sex, male, n (%) | 18 (52.9) | 21 (70) | 0.163 |
| Antiplatelet agentsa), n (%) | 1 (2.9) | 7 (23.3) | 0.021 |
| Coagulopathy, n (%) | 0 | 0 | NA |
| Thrombocytopeniab), n (%) | 1 (2.9) | 0 | 0.999 |
| Size, mm, mean±SD | 22.3±3.4 | 23.2±4.7 | 0.405 |
| Locationc), n (%) | 0.331 | ||
| Right colon | 19 (55.9) | 21 (70) | |
| Left colon | 8 (23.5) | 3 (10) | |
| Rectum | 7 (20.6) | 6 (20) | |
| Morphology, n (%) | 0.495 | ||
| Is | 4 (11.8) | 6 (20) | |
| II (IIa, IIb, or IIa + IIc) | 30 (88.2) | 24 (80) | |
| Histology, n (%) | 0.604 | ||
| TA, TVA, or VA | 28 (82.4) | 21 (70) | |
| SSA/P | 5 (14.7) | 8 (26.7) | |
| Superficial submucosal cancer | 1 (2.9) | 1 (3.3) |
Table 4.
| Variables | Korean CMI-EMR group (n=34) | US CMI-EMR group (n=30) | p-value |
|---|---|---|---|
| Device for CMI-EMR or ESD, n (%) | < 0.001 | ||
| Endoknife | 11 (32.4) | 27 (90) | |
| Tip of snare | 23 (67.6) | 3 (10) | |
| Submucosal injection solution, n (%) | < 0.001 | ||
| Saline-based solution only | 12 (35.3) | 23 (76.7) | |
| Adjuvant solutiona) | 22 (64.7) | 7 (23.3) | |
| Resection time, minutes, mean±SD | 12.7±7.0 | 18.7±11.3 | 0.011 |
| Gross en bloc resection, n (%) | 32 (94.1) | 24 (80) | 0.133 |
| Histologic complete resection, n (%) | 26 (76.5) | NAb) | NA |
| Complications | |||
| Postprocedural hemorrhage, n (%) | 1 (2.9) | 0 | 0.999 |
| Perforation, n (%) | 2 (5.9) | 0 | 0.494 |
CMI-EMR, endoscopic mucosal resection with circumferential mucosal incision; ESD, endoscopic submucosal dissection; SD, standard deviation; NA, not applicable.
a) Adjuvant solution indicates the use of sodium hyaluronate, methylcelluose, hetastarch, and/or 10% glycerol.
b) Specimens of American cases were submitted for routine histopathology in accordance with standard hospital protocols, which include neither spreading of the specimens nor 2 mm-thick slicing for histologic evaluation, and thus the histologic complete resection rate based on the microscopic evaluation of the resection margin was not available.



PDF
Citation
Print


XML Download